Wind数据显示，截至8月12日，今年以来南向资金累计净流入超9100亿港元，创年度净流入额历史 新高，显著超过2024年净流入的8078.69亿港元。据中国证券报记者统计，在今年以来南向资金交易的 145个交易日中，南向资金出现净流入的交易日有123个，占比超八成。 在今年以来南向资金大幅流入的带动下，港股市场表现亮眼，截至8月12日收盘，恒生指数累计涨 逾24%，恒生科技指数累计涨逾21%，恒生指数成分股中总市值超1万亿港元的股票均上涨，平均涨幅 超过30%。 近期，港股市场出现一定震荡。机构人士认为，外部预期调整可能是主要原因，预期变动会导致市 场波动较大，但这并未改变港股市场的中期配置逻辑。港股市场或吸引南向资金持续流入，支撑港股继 续向上。 净流入金额为去年同期两倍多 今年以来，南向资金大幅流入港股市场，是今年以来港股市场最大的增量资金来源。 Wind数据显示，截至8月12日，南向资金今年以来累计净流入9102.88亿港元，创年度净流入金额历 史新高，历史首次超过9100亿港元，为2024年同期的2倍多。其中，4月9日单日净流入355.86亿港元， 创单日净流入纪录。在今年以来南向资金交易的145个 ...

数据显示，截至8月12日，今年以来南向资金累计净流入超9100亿港元，创年度净流入额历史新高，显 著超过2024年净流入的8078.69亿港元。据中国证券报记者统计，在今年以来南向资金交易的145个交易 日中，南向资金出现净流入的交易日有123个，占比超八成。 在今年以来南向资金大幅流入的带动下，港股市场表现亮眼，截至8月12日收盘，恒生指数累计涨逾 24%，恒生科技指数累计涨逾21%，恒生指数成分股中总市值超1万亿港元的股票均上涨，平均涨幅超 过30%。 近期，港股市场出现一定震荡。机构人士认为，外部预期调整可能是主要原因，预期变动会导致市场波 动较大，但这并未改变港股市场的中期配置逻辑。港股市场或吸引南向资金持续流入，支撑港股继续向 上。 ● 本报记者 吴玉华 净流入金额为去年同期两倍多 今年以来，南向资金大幅流入港股市场，是今年以来港股市场最大的增量资金来源。 数据显示，截至8月12日，南向资金今年以来累计净流入9102.88亿港元，创年度净流入金额历史新高， 历史首次超过9100亿港元，为2024年同期的2倍多。其中，4月9日单日净流入355.86亿港元，创单日净 流入纪录。在今年以来南向资金交易的1 ...

Group 1 - Southbound capital has seen a cumulative net inflow of 9102.88 billion HKD as of August 12, marking a historical high and more than double the amount from the same period in 2024 [1][2] - The Hang Seng Index has risen over 24% year-to-date, with the Hang Seng Technology Index up over 21%, driven by significant inflows from southbound capital [1][4] - The majority of southbound capital inflow days have been positive, with 123 out of 145 trading days showing net inflows, accounting for over 80% [1][2] Group 2 - Southbound capital has increased its holdings in financial, information technology, and consumer discretionary sectors, with respective market values of 14320.41 billion HKD, 11167.63 billion HKD, and 7362.45 billion HKD [2][3] - Major stocks held by southbound capital include Tencent Holdings with over 5600 billion HKD, and several others like China Mobile and Alibaba with holdings exceeding 2000 billion HKD [3][5] - The healthcare, materials, and information technology sectors have led the market, with respective increases of 75.96%, 67.53%, and 36.27% year-to-date [4][5] Group 3 - Recent market fluctuations are attributed to external expectation adjustments, but the medium-term investment logic for the Hong Kong market remains unchanged [6][7] - Analysts predict that southbound capital inflows could exceed 1 trillion HKD for the year, indicating strong ongoing interest in the Hong Kong market [6][7] - The current valuation of the Hong Kong market is at a historical mid-to-high level, suggesting potential for upward movement [7]

Group 1 - The stock price of TianKang as of August 12, 2025, closed at 35.98 yuan, down 0.96% from the previous trading day, with a trading volume of 63,031 hands and a transaction amount of 226 million yuan [1] - TianKang's main business includes the research, production, and sales of pharmaceutical products. The company recently hosted a summit on innovative immunotherapy clinical transformation research, focusing on cutting-edge developments in the field of immunotherapy [1] - Chairman Zheng Hanjie stated at the summit that China's innovative drug industry is transitioning from "catching up" to "running alongside" and even "leading" [1] Group 2 - On the evening of August 12, the company announced a change in its continuous supervision sponsor representative, with Wang Ning replacing Liu Xiangmao to continue the supervision work [1] - The global pioneering small molecule drug CKBA, which the company is involved in developing, received attention at the summit. This drug targets the treatment of skin diseases such as vitiligo [1]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-065 华润双鹤药业股份有限公司 关于设立华润双鹤产业基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 重要内容提示： ? 交易简要内容：华润双鹤药业股份有限公司(以下简称"华润 双鹤"或"公司")拟投资设立华润双鹤生物医药产业基金(呼和浩特) 投资合伙企业(有限合伙)(暂定名，以工商核准名为准，以下简称"华 润双鹤产业基金"或"该基金")，基金目标募集规模为 5 亿元人民 币，公司及全资子公司双鹤(北京)生物技术有限公司(以下简称"双鹤 生物")拟以自有资金出资不超过 8,700 万元人民币，占基金总出资额 的比例不超过 17.40%。 ? 本次交易构成关联交易，不构成重大资产重组。 ? 本次交易金额超过 3,000 万元，未超过公司 2024 年度经审计 净资产的 5%，已经董事会审议批准，无需提交股东会审议。 ? 过去 12 个月内，除日常关联交易及本次交易外，公司拟以自 有资金 4,000 万元人民币与华润医药投资有限公司等 11 ...

Core Viewpoint - The market is witnessing a resurgence of the economic and quality factors that have been suppressed for a long time, leading to a significant improvement in the effectiveness of cyclical investments [1][2]. Group 1: Market Trends - The general sentiment in recent years has been that cyclical investments have become more challenging, with a "barbell" strategy being the primary choice. However, this year, cyclical and quality factors have regained market leadership, with two major indices representing active public funds outperforming most broad-based indices [2][5]. - The proportion of high-growth industries in Q1 2025 has significantly increased from 11.45% at the end of 2024 to 22.14%, marking a new high in the number of listed companies showing marginal improvements in economic conditions since 2010 [5]. Group 2: Industry Developments - Various new momentum sectors such as AI, robotics, semiconductors, military industry, innovative pharmaceuticals, and new consumption have made breakthroughs this year, alongside traditional cyclical and manufacturing sectors optimizing their supply structures [5][10]. - The market consensus on cyclical investment themes is strengthening as more technology-driven industries enter a phase of performance realization, particularly in TMT and innovative pharmaceuticals [10]. Group 3: Institutional Participation - Institutional investors skilled in cyclical investments have shown a significant increase in market participation enthusiasm, gradually reclaiming pricing power over quality targets and industries [13]. - Since June, the number of new institutional accounts has surged to historical highs, nearly recovering to levels seen in 2021, becoming a crucial source of incremental capital in the current market rally [13].

Group 1 - The core point of the news is that East China Pharmaceutical has signed an exclusive commercialization agreement for the oral formulation VC005 with Jiangsu Weikail Pharmaceutical Technology Co., Ltd, which is now effective [1] - East China Pharmaceutical (Hangzhou) has obtained exclusive commercialization rights for VC005 in mainland China, with an initial payment of 50 million RMB and potential milestone payments up to 180 million RMB [1] - Jiangsu Weikail has a pipeline of innovative drugs with multiple clinical projects in various stages, covering indications such as cardiovascular, oncology, autoimmune, and inflammatory diseases [1] Group 2 - VC005 is a novel, potent, and selective second-generation oral JAK1 inhibitor, developed for treating inflammatory and autoimmune diseases, with ongoing clinical development for conditions like moderate to severe atopic dermatitis and ankylosing spondylitis [2] - The clinical efficacy of VC005 in moderate to severe atopic dermatitis has shown comparable results to Upadacitinib, with rapid relief of itching observed on the day of administration [2] - VC005 is also in various stages of clinical trials for other indications, including ankylosing spondylitis and rheumatoid arthritis, with a sustained-release formulation under development [2]

Core Insights - The performance of private equity products reached a historical high in July 2025, with A-share indices showing significant upward trends, with the Shanghai Composite Index rising by 3.74%, the Shenzhen Component Index by 5.20%, and the ChiNext Index by 8.14% [1] - A total of 2,761 private equity products achieved historical net value highs in July 2025, representing approximately 60.43% of the products with performance data available for nearly one year [1] - Among these products, 1,214 were quantitative, while 1,547 were non-quantitative, with stock strategy products being the most prevalent, accounting for about 60% [1][2] Group 1: Product Performance - The majority of high-performing products came from private equity firms with assets under management below 500 million, totaling 1,122 products, while 379 products were from firms managing over 10 billion [2] - There were 21 products that had been established for over 10 years, with 15 of them classified as "Double Ten Funds," indicating annualized returns exceeding 10% [2] Group 2: Strategy Breakdown - The top-performing private equity products by strategy included 1,654 stock strategy products, 393 multi-asset strategy products, 327 futures and derivatives strategy products, 290 bond strategy products, and 97 combination fund products [1][2] - In the quantitative stock strategy category, there were 478 products, with the top 20 yielding over a specified threshold [6][10] Group 3: Notable Firms and Managers - Notable firms included Hainan Shengfeng Private Equity, which had a product ranked 9th among the top 20, with a recent scale of approximately *** billion and a near one-year return close to ***% [10] - The top-performing product in the subjective long strategy category was managed by Nengjing Investment Holdings, which had two products in the top rankings [11][13] Group 4: Sector Insights - The private equity market is currently characterized by a bullish sentiment, with high expectations for quality growth stocks, particularly in sectors like innovative pharmaceuticals, AI, and stablecoin financial innovations [5] - The bond strategy products also showed strong performance, with 203 products achieving historical highs, and the top five returns coming from firms like Yuankang Private Equity and Jiaze Fund [24][25]

Group 1 - Jishi Media (吉视传媒) clarifies that it does not engage in "State-owned Cloud" related businesses and does not invest in currently released films [1] - Haishi Pharmaceutical (海思科) received approval for clinical trials of its innovative drug HSK47977, a potential First-In-Class treatment for non-Hodgkin lymphoma [2] - Baiyun Airport (白云机场) signed a 10-year cooperation contract with China Duty Free Group for operating the T3 terminal's outbound duty-free project [3] Group 2 - ST Huamei (ST华微) announced that it failed to rectify fund occupation issues by the deadline, leading to a stock suspension starting August 13, 2025 [4] - Zhenlei Technology (臻镭科技) reported a 73.64% increase in revenue to 205 million yuan and a 1006.99% increase in net profit to approximately 62.32 million yuan for the first half of 2025 [5] - Jiangte Electric (江特电机) announced a change in actual controllers to Wang Xin and Zhu Jun following a share transfer [6] Group 3 - ST Shengtun (ST盛屯) will remove other risk warnings and change its stock name to "Shengtun Mining" effective August 14, 2025, with a trading limit increase from 5% to 10% [7] - Jin Chengzi (金橙子) plans to acquire 55% of Samit Optoelectronics through a share issuance and cash payment, with stock resuming trading on August 13 [8][9] - China Unicom (中国联通) proposed a cash dividend of 1.112 yuan per 10 shares, totaling approximately 3.477 billion yuan [10] Group 4 - China Shipbuilding (中国船舶) announced the buyout price for dissenting shareholders at 30.02 yuan per share, with a premium of 28.25% over the closing price [11] - Shuangyi Technology (双一科技) disclosed plans by its controlling shareholder to reduce holdings by up to 1.31 million shares, representing 0.7923% of total shares [12] - ST Xiachuang (ST峡创) will remove other risk warnings and change its stock name to "Haixia Innovation" effective August 14, 2025 [13] Group 5 - Yuhua Tian (玉禾田) stated that the small shareholding of Zhiyuan Innovation in its subsidiary does not significantly impact its operations [14] - Baichuan Co. (百川股份) announced that its chairman plans to reduce his stake by up to 3% due to personal financial needs [14]

Core Viewpoint - The A-share market has shown a strong upward trend since July, with the Shanghai Composite Index surpassing 3600 points for the fourth time since 2007, 2015, and 2021, indicating a robust market recovery and investor sentiment [2] Group 1: Market Performance - Since September 2024, A-shares and Hong Kong stocks have experienced a multi-sector rotation upward, with sectors like dividends, artificial intelligence, banking, and innovative pharmaceuticals showing active performance [2] - As of August 6, 2023, 80 actively managed equity funds have increased by over 60% this year, primarily from leading fund managers such as E Fund, Huatai-PineBridge, and GF Fund [4] - The North Exchange Index has surged over 110% in the past year, with several funds outperforming this index, including the CITIC Construction Investment North Exchange Select Fund, which has seen a rise of over 200% [5][6] Group 2: Fund Performance - A total of 90 actively managed equity funds have achieved an annualized return of over 15% over the past three years, with E Fund leading with seven products [8] - The annualized return for the entire market's active equity funds is only -1.99%, highlighting the strong performance of select funds [9] - In the past five years, only 21 products have exceeded a 15% annualized return, indicating the challenges faced in the broader market [9] Group 3: Sector Insights - The innovative pharmaceutical sector has seen a strong rebound, with multiple stocks doubling in value this year, driven by fundamental growth prospects [11] - Fund managers express confidence in the sustainability of the current pharmaceutical market trends, emphasizing the potential for continued growth in innovative drugs and medical services [11] - The technology sector, particularly cloud computing and AI, is viewed as having long-term growth potential, although some managers anticipate short-term volatility due to prior gains [12] Group 4: Investment Outlook - The North Exchange remains at a high valuation, with some signs of bubble formation, but medium to long-term investment potential is still seen as favorable [13]